The company have substantially advanced the development of the novel treatment for cardiac amyloidosis, utilizing the investigational drug. Early trial data reveals potential outcomes for patients diagnosed by this debilitating condition. The emphasis underscores BridgeBio's commitment to addressing critical medical requirements in the cardiology f